SMARCA4:

Brittany A Borden1, Adela Rodriguez-Hernandez2, Magan Trottier3

  • 1Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.

Gynecologic oncology
|October 14, 2025
PubMed
概括

患有SMARCA4生殖系致病性/可能致病性变体 (gPV) 的个体具有早期发病卵巢癌的高风险,特别是卵巢高血性类型 (SCCOHT) 小细胞癌. 这凸显了在基因测试和监测中对SMARCA4的需求.